B of A Securities Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Positive 56.9%

Neg 0% Neu 0% Pos 56.9%

B of A Securities analyst Tazeen Ahmad initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $35.